Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH. ASX:FPH) announced today that it will introduce the latest addition to its range of nasal masks at the European Respiratory Society (ERS) meeting which will be held from 27 September to 1 October in Vienna.

The new FlexiFitTMSeries HC405 nasal mask is intended for use in the treatment of Obstructive Sleep Apnea (OSA).  The HC405 incorporates Fisher & Paykel Healthcares FlexiFit TM Cushion Technology – designed to provide an increased range of movement and to conform automatically to most face shapes.

A new feature of the mask is a front swivel with a recessed flow diffuser for additional patient comfort.  The new mask also includes the company’s patented glider technology which provides stability and allows freedom of movement.

The new mask will be released to most of the company’s major international markets during October and November.

“We’re delighted to be offering this significant addition to our range of masks, and we are confident it has the potential to further improve patient comfort and compliance with CPAP therapy”, said Michael Daniell, Fisher & Paykel Healthcare’s Managing Director and CEO.

Further information can be obtained by contacting Michael Daniell on +64 9 574 0161 or Tony Barclay on +64 9 574 0119 at Fisher & Paykel Healthcare Corporation Limited or by visiting the company’s website at www.fphcare.com.  A high resolution image may be obtained on request from  dale.noel@fphcare.co.nz